# Cytoflavin in Combination With Reperfusion in Stroke Patients

> **NCT05297851** · — · COMPLETED · sponsor: **POLYSAN Scientific & Technological Pharmaceutical Company** · enrollment: 200 (actual)

## Conditions studied

- Acute Stroke

## Interventions

- **DRUG:** Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT05297851
- **Lead sponsor:** POLYSAN Scientific & Technological Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-10
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-03-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297851, "Cytoflavin in Combination With Reperfusion in Stroke Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05297851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*